EP Patent

EP4150078A1 — Methods and compositions for the adar-mediated editing of argininosuccinate lyase (asl)

Assigned to Korro Bio Inc · Expires 2023-03-22 · 3y expired

What this patent protects

The present invention relates to methods and compositions for editing an ASL polynucleotide, e.g., an ASL polynucleotide comprising a SNP associated with argininosuccinate lyase deficiency. The invention also relates to methods and compositions for treating or preventing arginino…

USPTO Abstract

The present invention relates to methods and compositions for editing an ASL polynucleotide, e.g., an ASL polynucleotide comprising a SNP associated with argininosuccinate lyase deficiency. The invention also relates to methods and compositions for treating or preventing argininosuccinate lyase deficiency in a subject.

Drugs covered by this patent

Patent Metadata

Patent number
EP4150078A1
Jurisdiction
EP
Classification
Expires
2023-03-22
Drug substance claim
No
Drug product claim
No
Assignee
Korro Bio Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.